SCHEMBL4239792

SCHEMBL4239792

N#Cc1ccc(C(=O)Nc2nc3c(C(=O)O)cccc3[nH]2)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.65
RAB9A P51151 6/20 0.65
MAOB P27338 3/20 0.56
ADORA2A P29274 3/20 0.56
ADORA2B P29275 1/20 0.56
ADORA1 P30542 1/20 0.56
IRAK4 Q9NWZ3 1/20 0.52
PARP1 P09874 3/20 0.51
PKM P14618 3/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
SCD O00767 1/20 0.48
KDM4E B2RXH2 2/20 0.48
HPGD P15428 1/20 0.48
PRSS12 P56730 1/20 0.46
OPRK1 P41145 1/20 0.45
KLF5 Q13887 1/20 0.45
TP53 P04637 1/20 0.45
HSD17B10 Q99714 1/20 0.45
DHODH Q02127 1/20 0.44
CYP11B1 P15538 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4235830 0.97 NPC1 (0.61) NPC1RAB9AMAOBADORA2AADORA2B
SCHEMBL4242710 0.88 IRAK4 (0.68) NPC1RAB9AMAOBADORA2AADORA2B
SCHEMBL4247108 0.88 MAOB (0.54) NPC1RAB9AMAOBADORA2AADORA2B
SCHEMBL4244085 0.88 IRAK4 (0.53) NPC1RAB9AMAOBADORA2AADORA2B
SCHEMBL4244245 0.85 MAOB (0.65) NPC1RAB9AMAOBADORA2AADORA2B
SCHEMBL4243664 0.85 DHODH (0.62) NPC1RAB9AMAOBADORA2AADORA2B
SCHEMBL4239705 0.85 IRAK4 (0.60) NPC1RAB9AMAOBADORA2AADORA2B
SCHEMBL4239768 0.84 MAOB (0.49) NPC1RAB9AMAOBADORA2AADORA2B
SCHEMBL1202398 0.84 NPC1 (0.59) NPC1RAB9AMAOBADORA2AADORA2B
SCHEMBL4240247 0.83 KDM4E (0.61) NPC1RAB9AMAOBADORA2AADORA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8946259-B2 Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors HIGH POINT PHARMACEUTICALS, LLC (US) 2015-02-03 US disclosed
US-20140066477-A1 Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors HIGH POINT PHARMACEUTICALS, LLC (US) 2014-03-06 US disclosed
US-8598353-B2 Benzazole derivatives, compositions, and methods of use as β-secretase inhibitors HIGH POINT PHARMACEUTICALS, LLC (US) 2013-12-03 US disclosed
EP-1863771-B1 BENZAZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE AS B-SECRETASE INHIBITORS HIGH POINT PHARMACEUTICALS LLC (US) 2012-11-07 EP disclosed
EP-2457901-A1 Benzazole derivatives, compositions, and methods of use as B-secretase inhibitors High Point Pharmaceuticals, LLC (US) 2012-05-30 EP disclosed
US-20090326006-A1 Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors VTVX HOLDINGS II LLC 2009-12-31 US disclosed
US-20060223849-A1 Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors HIGH POINT PHARMACEUTICALS, LLC 2006-10-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326006-A1 Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors BACE1, BACE2, APP NPC1 188/4885RAB9A 2719/4885MAOB 269/4885
US-20060223849-A1 Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors BACE1, BACE2, APP NPC1 188/4885RAB9A 2719/4885MAOB 269/4885
US-20140066477-A1 Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors BACE1, BACE2, APP NPC1 188/4885RAB9A 2719/4885MAOB 269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.